- Home
- CION vs FBRX Comparison
CION vs FBRX Comparison
Compare CION & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CION | FBRX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.0M | 379.3M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CION | FBRX |
|---|---|---|
| Price | $6.71 | $22.23 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 707.1K | 175.9K |
| Earning Date | 03-12-2026 | 04-06-2026 |
| Dividend Yield | ★ 17.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.50 | $4.91 |
| 52 Week High | $11.07 | $35.62 |
Technical Indicators
Market Signals| Indicator | CION | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 19.83 | 28.50 |
| Support Level | N/A | $21.86 |
| Resistance Level | $10.30 | $22.61 |
| Average True Range (ATR) | 0.24 | 2.18 |
| MACD | -0.07 | -0.68 |
| Stochastic Oscillator | 11.22 | 0.00 |
Price Performance
Historical ComparisonAbout CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).